Shenzhen Kangtai Biological Products Co Ltd is a human vaccine research and development company. The company is engaged in the research and development, production and sales of recombinant hepatitis B vaccine, b -type influenza Haemophilus conjugate vaccine, measles-rubella combined live attenuated vaccine, cell-free baibai broke b Haemophilus influenzae vaccine and other products.
1992
n/a
LTM Revenue $419M
LTM EBITDA $127M
$2.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BioKangtai has a last 12-month revenue of $419M and a last 12-month EBITDA of $127M.
In the most recent fiscal year, BioKangtai achieved revenue of $479M and an EBITDA of $173M.
BioKangtai expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See BioKangtai valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $479M | $400M | XXX | XXX | XXX |
Gross Profit | $367M | $366M | XXX | XXX | XXX |
Gross Margin | 77% | 91% | XXX | XXX | XXX |
EBITDA | $173M | $115M | XXX | XXX | XXX |
EBITDA Margin | 36% | 29% | XXX | XXX | XXX |
Net Profit | $174M | -$18.3M | XXX | XXX | XXX |
Net Margin | 36% | -5% | XXX | XXX | XXX |
Net Debt | n/a | $161M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, BioKangtai's stock price is CNY 15 (or $2).
BioKangtai has current market cap of CNY 16.3B (or $2.2B), and EV of CNY 18.1B (or $2.5B).
See BioKangtai trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$2.5B | $2.2B | XXX | XXX | XXX | XXX | $0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, BioKangtai has market cap of $2.2B and EV of $2.5B.
BioKangtai's trades at 6.0x LTM EV/Revenue multiple, and 19.7x LTM EBITDA.
Analysts estimate BioKangtai's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for BioKangtai and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $2.5B | XXX | XXX | XXX |
EV/Revenue | 6.2x | XXX | XXX | XXX |
EV/EBITDA | 21.7x | XXX | XXX | XXX |
P/E | 44.1x | XXX | XXX | XXX |
P/E/Growth | 1.1x | XXX | XXX | XXX |
EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBioKangtai's NTM/LTM revenue growth is 14%
BioKangtai's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, BioKangtai's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate BioKangtai's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for BioKangtai and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | -16% | XXX | XXX | XXX | XXX |
EBITDA Margin | 29% | XXX | XXX | XXX | XXX |
EBITDA Growth | -33% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 43% | XXX | XXX | XXX | XXX |
Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
Opex per Employee | n/a | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | 34% | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 14% | XXX | XXX | XXX | XXX |
Opex to Revenue | 54% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
CSL | XXX | XXX | XXX | XXX | XXX | XXX |
Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioKangtai acquired XXX companies to date.
Last acquisition by BioKangtai was XXXXXXXX, XXXXX XXXXX XXXXXX . BioKangtai acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was BioKangtai founded? | BioKangtai was founded in 1992. |
Where is BioKangtai headquartered? | BioKangtai is headquartered in China. |
Is BioKangtai publicy listed? | Yes, BioKangtai is a public company listed on SHE. |
What is the stock symbol of BioKangtai? | BioKangtai trades under 300601 ticker. |
When did BioKangtai go public? | BioKangtai went public in 2017. |
Who are competitors of BioKangtai? | Similar companies to BioKangtai include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
What is the current market cap of BioKangtai? | BioKangtai's current market cap is $2.2B |
What is the current revenue of BioKangtai? | BioKangtai's last 12-month revenue is $419M. |
What is the current EBITDA of BioKangtai? | BioKangtai's last 12-month EBITDA is $127M. |
What is the current EV/Revenue multiple of BioKangtai? | Current revenue multiple of BioKangtai is 6.0x. |
What is the current EV/EBITDA multiple of BioKangtai? | Current EBITDA multiple of BioKangtai is 19.7x. |
What is the current revenue growth of BioKangtai? | BioKangtai revenue growth between 2023 and 2024 was -16%. |
Is BioKangtai profitable? | Yes, BioKangtai is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.